TSRO Share Price

Open 130.77 Change Price %
High 134.17 1 Day 2.60 1.99
Low 128.33 1 Week -3.75 -2.74
Close 133.36 1 Month 13.20 10.99
Volume 657374 1 Year 80.87 154.07
52 Week High 148.74
52 Week Low 29.51
TSRO Important Levels
Resistance 2 138.77
Resistance 1 136.54
Pivot 131.95
Support 1 130.18
Support 2 127.95
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.70 0.20%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
RITT 0.06 -45.45%
More..

TESARO, Inc. (NASDAQ: TSRO)

TSRO Technical Analysis 4
As on 2nd Dec 2016 TSRO Share Price closed @ 133.36 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 71.67 & Buy for SHORT-TERM with Stoploss of 119.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSRO Target for December
1st Target up-side 156.26
2nd Target up-side 170.67
3rd Target up-side 185.09
1st Target down-side 115.12
2nd Target down-side 100.71
3rd Target down-side 86.29
TSRO Other Details
Segment EQ
Market Capital 430751968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.tesarobio.com
TSRO Address
TSRO
1000 Winter Street
Suite 3300
Waltham, MA 02451
United States
Phone: 339-970-0900
Interactive Technical Analysis Chart TESARO, Inc. ( TSRO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TESARO, Inc.
TSRO Business Profile
TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.